Topics

Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications

15:38 EST 28 Nov 2018 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
TRUXIMA® is the first rituximab biosimilar to be approved in the United States Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and ...

Other Sources for this Article

Celltrion, Inc.
IR Contacts:
Josh Hwang, +82 32 850 5171 / Josh.hwang@celltrion.com

PR Contacts:
Gunn Lee, +82 32 850 5168 / Gunhyuk.lee@celltrion.com
Heewon Park, +82 32 850 5356 / Heewon.park@celltrion.com

Teva Pharmaceutical Industries Ltd.
IR Contacts:
Kevin C. Mannix, (215) 591-8912
Ran Meir, 972 (3) 926-7516

PR Contacts:
United States, Doris Saltkill, 913-777-3343
Israel, Yonatan Beker, 972 (54) 888 5898

NEXT ARTICLE

More From BioPortfolio on "Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications"

Quick Search

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...